The agenda for continuing medical education - Limiting industry's influence

New England Journal of Medicine

Volumn 361, Issue 25, 2009, Pages 2478-

  Morris, Lewis ^a   Taitsman, Julie K ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

ACCREDITATION; CONTINUING EDUCATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; EDUCATION PROGRAM; EPILEPSY; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH PROMOTION; MEDICAL EDUCATION; MEDICAL SOCIETY; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; REIMBURSEMENT; SHORT SURVEY;

EID: 72449136664     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb0905411     Document Type: Article

References (15)

1. ACCME annual report data 2007. Chicago: Accreditation Council for Continuing Medical Education, August 28, 2008. (Accessed November 23, 2009, at http://www.accme.org/dir-docs/doc-upload/207fa8e2-bdbe-47f8-9b65-52477f9faade- uploaddocument.pdf.)
2. ACCME standards for commercial support: standards to ensure the independence of CME activities. Chicago: Accreditation Council for Continuing Medical Education, 2007. (Accessed November 23, 2009, at http://www.accme.org/ dir-docs/doc-upload/68b2902a-fb73-44d1-8725-80a1504e520c-uploaddocument.pdf.)
3. Institute of Medicine. Conflict of interest in medical research, education, and practice. Washington, DC: National Academies Press, 2009.
4. 42 U.S.C. § 1320a-7b(b).
5. 21 U.S.C. § 301 et seq.
6. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026
7. 31 U.S.C. § 3729 et seq.
8. Warner-Lambert to pay $430 million to resolve criminal & civil health care liability relating to off-label promotion. Press release of the U.S. Department of Justice, Washington, DC, May 13, 2004. (Accessed November 23, 2009 at http://www.usdoj.gov/opa/pr/2004/May/04-civ-322.htm.)
9. Occupational outlook handbook, physicians and surgeons, 2008-2009 edition. Washington, DC: U.S. Department of Labor, Bureau of Labor Statistics. (Accessed November 23, 2009, at http://www.bls.gov/oco/pdf/ocos074.pdf.)
10. Porucznik MA. Board members named for Center for Orthopaedic Advancement. Rosemont, IL: American Academy of Orthopaedic Surgeons, 2009. (Accessed November 23, 2009, at http:// www6.aaos.org/news/PDFopen/PDFopen.cfm?page-url= http://www.aaos.org/news/aaosnow/feb09/youraaos7.asp.)
11. Accredited CME is education that matters to patient care. Chicago: Accreditation Council for Continuing Medical Education, June 2008. (Accessed November 23, 2009, at http://www.accme.org/dir-docs/doc-upload/d6b96a50-084c- 485b-b71a-6b405b9c07d8-uploaddocument.pdf.)
12. Use of educational grants by pharmaceutical manufacturers. Washington, DC: Senate Committee on Finance, April 2007. (Accessed November 23, 2009, at http://www.senate.gov/~finance/ press/Bpress/2007press/prb042507a.pdf.)
13. Mainpro - Mainpro-M1 and Mainpro-C accreditation criteria for courses. Mississauga, ON, Canada: The College of Family Physicians of Canada, November 11, 2008. (Accessed November 23, 2009, at http://www.cfpc.ca/English/cfpc/cme/ mainpro/ maintenance%20of%20proficiency/m1%20and%20c%20criteria/ default.asp?s=1.)
14. New Pfizer CME grant criteria: frequently asked questions. New York: Pfizer Medical Education Group, July 18, 2008. (Accessed November 23, 2009, at https://www.pfizermededgrants.com/pfizercme/help/FAQs-Statement-on-CME-Support- updated-071808.pdf.)
15. Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009;301:1367-1372